Lawreen Heller Connors, PhD

Professor, Pathology & Laboratory Medicine

Lawreen Connors
72 E. Concord St Silvio Conte (K)

Biography

Dr. Connors received dual undergraduate degrees in Chemistry and Mathematics from Boston College, a master’s degree in Chemistry from Tufts University, and doctoral degree in Biochemistry from Boston University. She joined the Amyloidosis Center as a post-doctoral trainee in 1994, and obtained faculty appointments in the Departments of Biochemistry and Pathology & Laboratory Medicine in 1998 and 2009, respectively.
Dr. Connors focuses her basic science research on uncovering the protein and genetic determinants that underlie the formation of amyloid. The early stages of her career featured structural analyses of amyloid-causing transthyretin (TTR) mutants, mainly those causing cardiac dysfunction. More recently, her studies have been focused on wild-type TTR amyloidosis, an age-related disease now recognized as an under-appreciated cause of heart failure in the elderly. She has received continuous support from the NIH and foundation grants, as well as industry-sponsored research agreements, and has authored more than 100 peer-reviewed scholarly articles and book chapters.
In 2009, Dr. Connors played a major role in establishment of the Amyloid Pathology Diagnostic Testing Laboratory in the Amyloidosis Center, a CAP-accredited and CLIA-certified facility that offers histologic and molecular testing for amyloid. Dr. Connors teaches GMS classes on systemic amyloidosis, and has mentored more than 20 master’s, doctoral and postdoctoral students. She has served on multiple local, national and international committees, and is Director of the Amyloidosis Center Gerry Laboratory and Co-Director of the Amyloid Pathology Diagnostic Testing Laboratory.

Other Positions

  • Associate Professor, Biochemistry, Boston University School of Medicine
  • Member, Amyloidosis Center, Boston University
  • Member, Evans Center for Interdisciplinary Biomedical Research, Boston University
  • Graduate Faculty (Primary Mentor of Grad Students), Boston University School of Medicine, Graduate Medical Sciences

Education

  • Boston University, PhD
  • Tufts University, MS
  • Boston College, BS

Classes Taught

  • GMSPA710

Publications

  • Published on 10/19/2021

    Peterle D, Klimtchuk ES, Wales TE, Georgescauld F, Connors LH, Engen JR, Gursky O. A Conservative Point Mutation in a Dynamic Antigen-binding Loop of Human Immunoglobulin ?6 Light Chain Promotes Pathologic Amyloid Formation. J Mol Biol. 2021 Oct 19; 433(24):167310. PMID: 34678302.

    Read at: PubMed
  • Published on 8/4/2021

    Staron A, Zheng L, Doros G, Connors LH, Mendelson LM, Joshi T, Sanchorawala V. Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer J. 2021 Aug 04; 11(8):139. PMID: 34349108.

    Read at: PubMed
  • Published on 11/10/2020

    Staron A, Connors LH, Zheng L, Doros G, Sanchorawala V. Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities. Blood Cancer J. 2020 11 10; 10(11):118. PMID: 33173025.

    Read at: PubMed
  • Published on 11/3/2020

    Torres-Arancivia CM, Chang D, Hackett WE, Zaia J, Connors LH. Glycosylation of Serum Clusterin in Wild-Type Transthyretin-Associated (ATTRwt) Amyloidosis: A Study of Disease-Associated Compositional Features Using Mass Spectrometry Analyses. Biochemistry. 2020 11 17; 59(45):4367-4378. PMID: 33141553.

    Read at: PubMed
  • Published on 7/30/2020

    Giadone RM, Liberti DC, Matte TM, Rosarda JD, Torres-Arancivia C, Ghosh S, Diedrich JK, Pankow S, Skvir N, Jean JC, Yates JR, Wilson AA, Connors LH, Kotton DN, Wiseman RL, Murphy GJ. Expression of Amyloidogenic Transthyretin Drives Hepatic Proteostasis Remodeling in an Induced Pluripotent Stem Cell Model of Systemic Amyloid Disease. Stem Cell Reports. 2020 08 11; 15(2):515-528. PMID: 32735824.

    Read at: PubMed
  • Published on 7/20/2020

    Schulman A, Connors LH, Weinberg J, Mendelson LM, Joshi T, Shelton AC, Sanchorawala V. Patient outcomes in light chain (AL) amyloidosis: The clock is ticking from symptoms to diagnosis. Eur J Haematol. 2020 Oct; 105(4):495-501. PMID: 32564450.

    Read at: PubMed
  • Published on 4/30/2020

    Dasari AKR, Hung I, Michael B, Gan Z, Kelly JW, Connors LH, Griffin RG, Lim KH. Structural Characterization of Cardiac Ex Vivo Transthyretin Amyloid: Insight into the Transthyretin Misfolding Pathway In Vivo. Biochemistry. 2020 05 19; 59(19):1800-1803. PMID: 32338497.

    Read at: PubMed
  • Published on 12/2/2019

    Lohrmann G, Pipilas A, Mussinelli R, Gopal DM, Berk JL, Connors LH, Vellanki N, Hellawell J, Siddiqi OK, Fox J, Maurer MS, Ruberg FL. Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis. J Card Fail. 2020 Sep; 26(9):753-759. PMID: 31805416.

    Read at: PubMed
  • Published on 7/15/2019

    Staron A, Connors LH, Ruberg FL, Mendelson LM, Sanchorawala V. A new era of amyloidosis: the trends at a major US referral centre. Amyloid. 2019 Dec; 26(4):192-196. PMID: 31306033.

    Read at: PubMed
  • Published on 6/12/2019

    Tahir UA, Doros G, Kim JS, Connors LH, Seldin DC, Sam F. Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure. Sci Rep. 2019 06 12; 9(1):8552. PMID: 31189919.

    Read at: PubMed

View 90 more publications: View full profile at BUMC

View all profiles